Roundtable Discussion: Is Bigger Always Better? Defining the Right Scale to Effectively Balance Yield, Safety & Cost

11:30 am - Wednesday 25th February 2026

  • Contrasting scalability limitations across vector types and how physical constraints shape commercial strategy
  • Discussing trade-offs between driving higher titres versus maintaining potency and how these challenges can differ across vector classes
  • Deciding between ‘scaling up’ and ‘scaling out’ and how this can be affected by modality, indication, and regulatory expectation

Speakers:

Staff Scientist
National Cancer Institute
Vice President - Process Development & Manufacturing
Obsidian Therapeutics